Last reviewed · How we verify
SEMAGLUTIDE
Semaglutide is a GLP-1 receptor agonist that mimics the action of the incretin hormone GLP-1 to enhance insulin secretion and reduce blood glucose levels.
At a glance
| Generic name | SEMAGLUTIDE |
|---|---|
| Modality | Recombinant protein |
| Phase | FDA-approved |
| First approval | 2017 |
Mechanism of action
Semaglutide works by activating the GLP-1 receptor, which helps the body produce more insulin when blood sugar is high and reduces the amount of glucose produced by the liver. This dual action effectively lowers blood glucose levels in people with diabetes.
Approved indications
Common side effects
- COVID-19
- Nausea
- Diabetic retinopathy
- Diarrhoea
- Constipation
- Decreased appetite
- Vomiting
- Dyspepsia
- Lipase increased
- Urinary tract infection
- Nasopharyngitis
- Cataract
Key clinical trials
- MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease (NA)
- A Study of a Weight Loss Intervention in People With Endometrial Cancer (EARLY_PHASE1)
- A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) (PHASE3)
- Semaglutide Use in Acute Pulmonary Embolism
- IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion (NA)
- Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss (PHASE2)
- Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide (PHASE2)
- Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SEMAGLUTIDE CI brief — competitive landscape report
- SEMAGLUTIDE updates RSS · CI watch RSS